Li, Y. & Nair, H. Trends in the global burden of lower respiratory infections: the knowns and the unknowns. Lancet Infect. Dis. 22, 1523–1525, (2022).
Google Scholar
Qu, B. & Zhang, D. Evaluation of COVID-19 booster vaccine effectiveness. Viruses 17, (2025).
Winklmeier, S. et al. Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva. Front. Immunol. 15, 1330864 (2024).
Google Scholar
Li, M. et al. Mucosal vaccines: strategies and challenges. Immunol. Lett. 217, 116–125, (2020).
Google Scholar
Zhao, K., Xie, Y., Lin, X. & Xu, W. The mucoadhesive nanoparticle-based delivery system in the development of mucosal vaccines. Int. J. Nanomed. 17, 4579–4598, (2022).
Google Scholar
Van der Ley, P. & Schijns, V. E. Outer membrane vesicle-based intranasal vaccines. Curr. Opin. Immunol. 84, 102376. (2023).
Google Scholar
Lei, H. et al. Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants. Signal Transduct. Target. Ther. 9, 311, (2024).
Google Scholar
Diniz, M. O. et al. Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2. Nat. Immunol. 23, 1324–1329, (2022).
Google Scholar
Nelson, C. E. et al. IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques. PLoS Pathog. 20, e1012339, (2024).
Google Scholar
Honda, T. et al. Intranasally inoculated SARS-CoV-2 spike protein combined with mucoadhesive polymer induces broad and long-lasting immunity. Vaccines 12, (2024).
Mettelman, R. C., Allen, E. K. & Thomas, P. G. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity 55, 749–780, (2022).
Google Scholar
Butnarasu, C. et al. Structural determinants of mucins in influenza virus inhibition: the role of sialylated glycans and molecular size. Int. J. Biol. macromolecules 307, 142357. (2025).
Google Scholar
Iseli, A. N. et al. The neuraminidase activity of influenza A virus determines the strain-specific sensitivity to neutralization by respiratory mucus. J. Virol. 97, e0127123. (2023).
Google Scholar
Pan, J., Duggal, N. K., Lakdawala, S. S., Rockey, N. C. & Marr, L. C. Mucin colocalizes with influenza virus and preserves infectivity in deposited model respiratory droplets. Environ. Sci. Technol. 59, 2192–2200, (2025).
Google Scholar
Agarwal, S., Veytsman, B., Fletcher, D. A. & Huber, G. Kinetics and optimality of influenza A virus locomotion. Phys. Rev. Lett. 133, 248402. (2024).
Google Scholar
Wilson, R., Dowling, R. B. & Jackson, A. D. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur. Respiratory J. 9, 1523–1530, (1996).
Google Scholar
Diamond, G., Legarda, D. & Ryan, L. K. The innate immune response of the respiratory epithelium. Immunol. Rev. 173, 27–38, (2000).
Google Scholar
Nowarski, R., Jackson, R. & Flavell, R. A. The stromal intervention: regulation of immunity and inflammation at the epithelial-mesenchymal barrier. Cell 168, 362–375, (2017).
Google Scholar
Kim, J., Ryu, S. & Kim, H. Y. Innate lymphoid cells in tissue homeostasis and disease pathogenesis. Mol. Cells 44, 301–309, (2021).
Google Scholar
Cortez, V. S. & Colonna, M. Diversity and function of group 1 innate lymphoid cells. Immunol. Lett. 179, 19–24, (2016).
Google Scholar
Meininger, I. et al. Tissue-specific features of innate lymphoid cells. Trends Immunol. 41, 902–917, (2020).
Google Scholar
Chan, L., Mehrani, Y., Minott, J. A., Bridle, B. W. & Karimi, K. Dendritic cell vaccines impact the type 2 innate lymphoid cell population and their cytokine generation in mice. Vaccines 11, (2023).
Li, Z., Roy, S. & Ranasinghe, C. IL-13Rα2 Regulates the IL-13/IFN-γ balance during innate lymphoid cell and dendritic cell responses to pox viral vector-based vaccination. Vaccines 9, (2021).
Sugimura, R. & Wang, C. Y. The role of innate lymphoid cells in cancer development and immunotherapy. Front. cell Develop. Biol. 10, 803563. (2022).
Google Scholar
Kim, D. Y. et al. The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J. Immunol. 186, 4253–4262, (2011).
Google Scholar
Li, W. et al. Research Progress On Dendritic Cells In Hepatocellular Carcinoma Immune Microenvironments. Biomolecules 14, (2024).
Seefeld, M. L. et al. Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake. Front. Immunol. 15, 1419527. (2024).
Google Scholar
Song, W. & Craft, J. T Follicular Helper Cell Heterogeneity. Annu. Rev. Immunol. 42, 127–152, (2024).
Google Scholar
Kumar Bharathkar, S. & Stadtmueller, B. M. Structural and Biochemical Requirements For Secretory Component Interactions With Dimeric IgA. J. Immunol. 213, 226–234, (2024).
Google Scholar
Cao, X., Zai, J., Zhao, Q., Xie, L. & Li, Y. Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody. Vaccine 40, 5757–5763, (2022).
Google Scholar
Chao, Y. X., Rötzschke, O. & Tan, E. K. The role of IgA in COVID-19. Brain Behav. Immun. 87, 182–183, (2020).
Google Scholar
Madissoon, E. et al. A spatially resolved atlas of the human lung characterizes a gland-associated immune niche. Nat. Genet. 55, 66–77, (2023).
Google Scholar
Ma, J. et al. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front. Immunol. 15, 1377374. (2024).
Google Scholar
Long, B. et al. Tissue-Resident Memory T Cells in Allergy. Clin. Rev. Allergy Immunol. 66, 64–75, (2024).
Google Scholar
Xie, D., Lu, G., Mai, G., Guo, Q. & Xu, G. Tissue-resident memory T cells in diseases and therapeutic strategies. Med. Commun. 6, e70053. (2025).
Google Scholar
Roy, R., Das, T. & Biswas, N. Orchestration of immune response by innate lymphoid cell subtype 2 at various tumor microenvironment, a suitable target for cancer immunotherapy. Int. Rev. Immunol. 43, 74–82, (2024).
Google Scholar
Wei, L., Abraham, D. & Ong, V. The Yin and Yang of IL-17 in Systemic Sclerosis. Front. Immunol. 13, 885609. (2022).
Google Scholar
Lapuente, D. et al. IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses. Mucosal Immunol. 11, 1265–1278, (2018).
Google Scholar
Pilapitiya, D., Wheatley, A. K. & Tan, H. X. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine 92, 104585. (2023).
Google Scholar
Martinuzzi, E. et al. A single dose of BNT162b2 messenger RNA vaccine induces airway immunity in severe acute respiratory syndrome coronavirus 2 naive and recovered coronavirus disease 2019 subjects. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 75, 2053–2059, (2022).
Google Scholar
Mostaghimi, D., Valdez, C. N., Larson, H. T., Kalinich, C. C. & Iwasaki, A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect. Dis. 22, e52–e58, (2022).
Google Scholar
Purushotham, J. N., van Doremalen, N. & Munster, V. J. SARS-CoV-2 vaccines: anamnestic response in previously infected recipients. Cell Res. 31, 827–828, (2021).
Google Scholar
Knisely, J. M. et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report. npj Vaccines 8, 53. (2023).
Google Scholar
McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385–391, (2024).
Google Scholar
Oh, J. E., et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci. Immunol. 6, eabj5129, (2021).
Google Scholar
Gagne, M. et al. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nat. Immunol. 25, 1913–1927, (2024).
Google Scholar
Zhang, X. et al. Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines. Expert Rev. Vaccines 23, 362–370, (2024).
Google Scholar
Hong, W., et al. A chimeric adenovirus-vectored vaccine based on Beta spike and Delta RBD confers a broad-spectrum neutralization against Omicron-included SARS-CoV-2 variants. MedComm 5, e539, (2024).
Google Scholar
Fuchs, J. et al. Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus. NPJ Vaccines 9, 205. (2024).
Google Scholar
Malloy, A. M. W. et al. Increased innate immune activation induces protective RSV-specific lung-resident memory T cells in neonatal mice. Mucosal Immunol. 16, 593–605, (2023).
Google Scholar
Lei, H. et al. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. Signal Transduct. Target. Ther. 7, 159, (2022).
Google Scholar
Sinha, D., Yaugel-Novoa, M., Waeckel, L., Paul, S. & Longet, S. Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses. Antivir. Res. 223, 105823. (2024).
Google Scholar
Rudenko, L., Yeolekar, L., Kiseleva, I. & Isakova-Sivak, I. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories. Vaccine 34, 5436–5441, (2016).
Google Scholar
Jorba, J. et al. Update on vaccine-derived polioviruses – worldwide, January 2017-June 2018. Mmwr. Morbidity Mortal. Wkly. Rep. 67, 1189–1194, (2018).
Google Scholar
Dotiwala, F. & Upadhyay, A. K. Next generation mucosal vaccine strategy for respiratory pathogens. Vaccines 11, (2023).
Li, Y., Jin, L. & Chen, T. The Effects of secretory IgA in the mucosal immune system. BioMed. Res. Int. 2020, 2032057. (2020).
Google Scholar
Zanin, M., Baviskar, P., Webster, R. & Webby, R. The interaction between respiratory pathogens and mucus. Cell Host Microbe 19, 159–168, (2016).
Google Scholar
Wallace, L. E., Liu, M., van Kuppeveld, F. J. M., de Vries, E. & de Haan, C. A. M. Respiratory mucus as a virus-host range determinant. Trends Microbiol. 29, 983–992, (2021).
Google Scholar
Huang, M., Zhang, M., Zhu, H., Du, X. & Wang, J. Mucosal vaccine delivery: a focus on the breakthrough of specific barriers. Acta pharmaceutica Sin. B 12, 3456–3474, (2022).
Google Scholar
Kayama, H. & Takeda, K. Regulation of intestinal homeostasis by innate and adaptive immunity. Int. Immunol. 24, 673–680, (2012).
Google Scholar
Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592–605, (2012).
Google Scholar
Wu, L., Xu, W., Jiang, H., Yang, M. & Cun, D. Respiratory delivered vaccines: current status and perspectives in rational formulation design. Acta Pharmaceutica Sin. B 14, 5132–5160, (2024).
Google Scholar
Ashhurst, A. S., et al. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nat. Commun. 13, 6972, (2022).
Google Scholar
Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y. & Kiyono, H. Nasal vaccines: solutions for respiratory infectious diseases. Trends Mol. Med. 29, 124–140, (2023).
Google Scholar
Kiyono, H. & Ernst, P. B. Nasal vaccines for respiratory infections. Nature 641, 321–330, (2025).
Google Scholar
Jeyanathan, M. et al. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight 7, (2022).
Löffler, P. Review: vaccine myth-buster – cleaning up with prejudices and dangerous misinformation. Front. Immunol. 12, 663280, (2021).
Google Scholar
Igyártó, B. Z. & Qin, Z. The mRNA-LNP vaccines – the good, the bad and the ugly? Front. Immunol. 15, 1336906, (2024).
Google Scholar
Xu, H., Cai, L., Hufnagel, S. & Cui, Z. Intranasal vaccine: factors to consider in research and development. Int. J. Pharmaceutics 609, 121180. (2021).
Google Scholar
Jin, Z., Gao, S., Cui, X., Sun, D. & Zhao, K. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines. Int. J. Pharmaceutics 572, 118731. (2019).
Google Scholar
Correa, V. A., Portilho, A. I. & De Gaspari, E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology 167, 124–138, (2022).
Google Scholar
Cappelli, L. et al. Self-assembling protein nanoparticles and virus like particles correctly display β-barrel from meningococcal factor H-binding protein through genetic fusion. PLoS One 17, e0273322, (2022).
Google Scholar
Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283, (2023).
Google Scholar
Lawson, L. B., Norton, E. B. & Clements, J. D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr. Opin. Immunol. 23, 414–420, (2011).
Google Scholar
Gao, Y. & Guo, Y. Research progress in the development of natural-product-based mucosal vaccine adjuvants. Front. Immunol. 14, 1152855. (2023).
Google Scholar
Kim, J. et al. Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy. Adv. Sci.11, e2403663, (2024).
Google Scholar
Chen, R. et al. A respiratory mucosal vaccine based on chitosan/aluminum adjuvant induces both mucosal and systemic immune responses. Int. J. Pharmaceutics 670, 125168. (2025).
Google Scholar
Zeng, L. Mucosal adjuvants: Opportunities and challenges. Hum. Vaccines Immunother. 12, 2456–2458, (2016).
Google Scholar
Freytag, L. C. & Clements, J. D. in Mucosal Immunology (Fourth Edition) (eds J. Mestecky et al.) 1183-1199 (Academic Press, 2015).
Clements, J. D. & Norton, E. B. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT. mSphere 3, (2018).
Tregoning, J. S., Russell, R. F. & Kinnear, E. Adjuvanted influenza vaccines. Hum. vaccines immunother. 14, 550–564, (2018).
Google Scholar
Maciel, M. Jr. et al. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice. PLoS One 14, e0224073, (2019).
Google Scholar
Pan, S.-C. et al. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study. Vaccine 37, 1994–2003, (2019).
Google Scholar
Eriksson, A. M., Schön, K. M. & Lycke, N. Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues1. J. Immunol. 173, 3310–3319 (2004). The Journal of Immunology.
Google Scholar
van der Lubben, I. M., Verhoef, J. C., Borchard, G. & Junginger, H. E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. Off. J. Eur. Federation Pharm. Sci. 14, 201–207, (2001).
Google Scholar
Wen, Z.-S., Xu, Y.-L., Zou, X.-T. & Xu, Z.-R. Chitosan Nanopart. Act. Adjuv. Promot. both Th1 Th2 Immune Responses Induc. Ovalbumin Mice 9, 1038–1055 (2011).
Google Scholar
Mills, K. H. G. et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A. 71, 726-732, (2003).
Wang, M. et al. Sulfated glucan can improve the immune efficacy of Newcastle disease vaccine in chicken. Int. J. Biol. Macromol. 70, 193–198, (2014).
Google Scholar
Mirza, Z., Soto, E. R., Dikengil, F., Levitz, S. M. & Ostroff, G. R. Beta-Glucan Particles as Vaccine Adjuvant Carriers. Methods Mol. Biol. 1625, 143–157, (2017).
Google Scholar
Tsukada, C. et al. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell. Immunol. 221, 1–5, (2003).
Google Scholar
Lei, H. et al. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Signal Transduct. Target. Ther. 5, 291, (2020).
Google Scholar
Dong, C. et al. Polycationic HA/CpG nanoparticles induce cross-protective influenza immunity in mice. ACS Appl. Mater. interfaces 14, 6331–6342, (2022).
Google Scholar
Hu, Y. et al. Highly enhanced antitumor immunity by a three-barreled strategy of the l-arginine-promoted nanovaccine and gene-mediated PD-L1 blockade. ACS Appl. Mater. interfaces 12, 41127–41137, (2020).
Google Scholar
Ko, S. Y. et al. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175, 3309–3317, (2005).
Google Scholar
Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109, (2023).
Google Scholar
Veldhoen, M. Interleukin 17 is a chief orchestrator of immunity. Nat. Immunol. 18, 612–621, (2017).
Google Scholar
Jaffar, Z., Ferrini, M. E., Girtsman, T. A. & Roberts, K. Antigen-specific Treg regulate Th17-mediated lung neutrophilic inflammation, B-cell recruitment and polymeric IgA and IgM levels in the airways. Eur. J. Immunol. 39, 3307–3314, (2009).
Google Scholar
Mosaheb, M. M., Reiser, M. L. & Wetzler, L. M. Toll-like receptor ligand-based vaccine adjuvants require intact MyD88 signaling in antigen-presenting cells for germinal center formation and antibody production. Front. Immunol. 8, 225, (2017).
Google Scholar
Liang, H. et al. The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine. npj Vaccines 4, 19. (2019).
Google Scholar
Lavelle, E. C. & Ward, R. W. Mucosal vaccines – fortifying the frontiers. Nat. Rev. Immunol. 22, 236–250, (2022).
Google Scholar
Wang, S., Liu, H., Zhang, X. & Qian, F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein cell 6, 480–503, (2015).
Google Scholar
Matos, M. N. et al. Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi. PLoS Neglected Trop. Dis. 11, e0005300, (2017).
Google Scholar
An, X. et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience 24, 103037, (2021).
Google Scholar
Allen, A. C. et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal Immunol. 11, 1763–1776, (2018).
Google Scholar
Sui, Y. et al. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight 6, (2021).
Wang, X. & Meng, D. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell 6, 170–184, (2015).
Google Scholar
Schmidt, A. et al. Inflammatory conditions shape phenotypic and functional characteristics of lung-resident memory T cells in mice. Nat. Commun. 16, 3612. (2025).
Google Scholar
Oltmanns, F. et al. Mucosal tumor vaccination delivering endogenous tumor antigens protects against pulmonary breast cancer metastases. J. Immunother. Cancer 12, (2024).
Paris, O., Mennechet, F. J. D. & Kremer, E. J. Human innate lymphoid cell activation by adenoviruses is modified by host defense proteins and neutralizing antibodies. Front. Immunol. 13, 975910, (2022).
Google Scholar
Lacaille-Dubois, M. A. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review. Phytomedicine Int. J. Phytother. Phytopharmacol. 60, 152905. (2019).
Google Scholar
Cibulski, S. et al. Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines. Vaccine 36, 55–65, (2018).
Google Scholar
Sun, M. et al. Anticancer effects of ginsenoside Rg3 (Review). Int. J. Mol. Med. 39, 507–518, (2017).
Google Scholar
Ko, S.-Y. et al. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor1. J. Immunol. 175, 3309–3317, (2005).
Google Scholar
Lee, Y.-S. et al. An α-GalCer analogue with branched ACYL chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 29, 417–425, (2011).
Google Scholar
Boyaka, P. N., McGhee, J. R., Czerkinsky, C. & Mestecky, J. Mucosal Vaccines: An Overview. (Mucosal Immunology. 855-874. (2005) Epub 2007 May 9.
Nochi, T. et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9, 572–578, (2010).
Google Scholar
Morein, B., Hu, K. F. & Abusugra, I. Current status and potential application of ISCOMs in veterinary medicine. Adv. drug Deliv. Rev. 56, 1367–1382, (2004).
Google Scholar
Lenarczyk, A. et al. ISCOM based vaccines for cancer immunotherapy. Vaccine 22, 963–974, (2004).
Google Scholar
Aguila, A. et al. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 24, 5201–5210, (2006).
Google Scholar
Singh, B. et al. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases. Int. J. Biol. Macromol. 110, 54–64, (2018).
Google Scholar
Sadeghi, S., Lee, W. K., Kong, S. N., Shetty, A. & Drum, C. L. Oral administration of protein nanoparticles: an emerging route to disease treatment. Pharmacol. Res. 158, 104685, (2020).
Google Scholar
Shakya, A. K., Chowdhury, M. Y. E., Tao, W. & Gill, H. S. Mucosal vaccine delivery: current state and a pediatric perspective. J. Controlled Release Off. J. Controlled Release Soc. 240, 394–413, (2016).
Google Scholar
Lopes, P. D. et al. Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge. Vaccine 36, 2630–2636, (2018).
Google Scholar
Cleary, J., Bromberg, L. & Magner, E. Adhesion of polyether-modified poly(acrylic acid) to mucin. Langmuir ACS J. Surf. Colloids 20, 9755–9762, (2004).
Google Scholar
Bernkop-Schnürch, A. Thiomers: a new generation of mucoadhesive polymers. Adv. drug Deliv. Rev. 57, 1569–1582, (2005).
Google Scholar
Sarma, P. P., Rai, A. & Baruah, P. K. Recent advances in the development of antibiotics-coated gold nanoparticles to combat antimicrobial resistance. Antibiotics 13, 124, (2024).
Google Scholar
Abdullah et al. Recent advances in the development of metal/metal oxide nanoparticle and antibiotic conjugates (MNP-Antibiotics) to address antibiotic resistance: review and perspective. Int J. Mol. Sci. 25, 8915, (2024).
Google Scholar
Kim, K. & Park, M. H. Advancing cancer treatment: enhanced combination therapy through functionalized porous nanoparticles. Biomedicines 12, (2024).
Parvin, N., Joo, S. W. & Mandal, T. K. Enhancing vaccine efficacy and stability: a review of the utilization of nanoparticles in mRNA vaccines. Biomolecules 14, (2024).
Kelly, H. G. et al. Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight 5, (2020).
Pyles, G. M. et al. Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against Bordetella pertussis respiratory infection in mice. Infect. Immun. 92, e0027024. (2024).
Google Scholar
Lacasta, A. et al. Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever. Front. Immunol. 13, 1015840. (2022).
Google Scholar
Subbarao, K. Live Attenuated Cold-Adapted Influenza Vaccines. Cold Spring Harbor perspectives in medicine 11, (2021).
Grohskopf, L. A., Sokolow, L. Z., Fry, A. M., Walter, E. B. & Jernigan, D. B. Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4) – United States, 2018-19 Influenza Season. Mmwr. Morbidity Mortal. Wkly. Rep. 67, 643–645, (2018).
Google Scholar
Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices–United States, 2013-2014. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports 62, 1-43 (2013).
Grohskopf, L. A. et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2020-21 Influenza Season. Mmwr. Recommendations Rep. : Morbidity Mortal. Wkly. Report. Recommendations Rep. 69, 1–24, (2020).
Google Scholar
Block, S. L. et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 31, 745–751, (2012).
Google Scholar
Belshe, R. B. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338, 1405–1412, (1998).
Google Scholar
De Villiers, P. J. et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28, 228–234, (2009).
Google Scholar
Amanna, I. J. Balancing the efficacy and safety of vaccines in the elderly. Open Longev. Sci. 6, 64–72, (2012).
Google Scholar
Boyaka, P. N. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9–16, (2017).
Google Scholar
Nigwekar, P. V. et al. Safety of Russian-backbone trivalent, live attenuated seasonal influenza vaccine in healthy subjects: open-label, non-randomized phase 4 study. Drug Saf. 41, 171–177, (2018).
Google Scholar
Kulkarni, P. S., Raut, S. K. & Dhere, R. M. A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac (®)) in India. Hum. Vaccines Immunotherapeutics 9, 122–124, (2013).
Google Scholar
Shurygina, A. P. et al. Truncated NS1 Influenza A virus induces a robust antigen-specific tissue-resident T-cell response and promotes inducible bronchus-associated lymphoid tissue formation in mice. Vaccines 13, (2025).
Avanthay, R. et al. Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model. PLoS Pathog. 20, e1012393, (2024).
Google Scholar
Rathnasinghe, R. et al. Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity. NPJ Vaccines 9, 169. (2024).
Google Scholar
Ko, K. H. et al. A vaccine platform targeting lung-resident memory CD4(+) T-cells provides protection against heterosubtypic influenza infections in mice and ferrets. Nat. Commun. 15, 10368. (2024).
Google Scholar
Fan, R. L. et al. Generation of live attenuated influenza virus by using codon usage bias. J. Virol. 89, 10762–10773, (2015).
Google Scholar
Stauft, C. B. et al. Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets. PLoS One 14, e0223784, (2019).
Google Scholar
Sarawar, S. et al. Longevity and mechanism of heterosubtypic protection induced by M2SR (M2-Deficient Single-Replication) live influenza virus vaccine in mice. Vaccines 10, (2022).
Hill-Batorski, L. et al. Quadrivalent formulation of intranasal influenza vaccine M2SR (M2-Deficient Single Replication) protects against drifted influenza A and B virus challenge. Vaccines 11, (2023).
Eiden, J. et al. M2-deficient single-replication influenza vaccine-induced immune responses associated with protection against human challenge with highly drifted H3N2 influenza strain. J. Infect. Dis. 226, 83–90, (2022).
Google Scholar
Eiden, J. et al. Intranasal M2SR (M2-Deficient Single Replication) H3N2 influenza vaccine provides enhanced mucosal and serum antibodies in adults. J. Infect. Dis. 227, 103–112, (2022).
Google Scholar
Eiden, J. et al. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial. Lancet Infect. Dis. 24, 1118–1129, (2024).
Google Scholar
Hill-Batorski, L. et al. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge. Vaccine 42, 2770–2780, (2024).
Google Scholar
Moser, M. J. et al. Intranasal single-replication influenza vector induces cross-reactive serum and mucosal antibodies against SARS-CoV-2 variants. Vaccines 11, (2023).
Zhao, T. et al. Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice. Vaccine 51, 126882. (2025).
Google Scholar
Wang, J. et al. A VLP-based vaccine displaying HBHA and MTP antigens of mycobacterium tuberculosis induces protective immune responses in M. tuberculosis H37Ra infected mice. Vaccines 11, (2023).
Mao, J. et al. Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection. Emerg. microbes Infect. 14, 2494702. (2025).
Google Scholar
Mao, J. et al. Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain. Nanomed. (Lond., Engl.) 19, 741–754, (2024).
Google Scholar
Meade, P. et al. Antigenic landscape analysis of individuals vaccinated with a universal influenza virus vaccine candidate reveals induction of cross-subtype immunity. J. Virol. 97, e0107022. (2023).
Google Scholar
Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med 15, eade4790. (2023).
Google Scholar
Rijnink, W. F. et al. Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses. J. Virol. 97, e0164622. (2023).
Google Scholar
Raha, J. R. et al. Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection. Vaccine 57, 127206. (2025).
Google Scholar
Pankhurst, T. E. et al. MAIT cells activate dendritic cells to promote T(FH) cell differentiation and induce humoral immunity. Cell Rep. 42, 112310. (2023).
Google Scholar
Imagawa, T., Arasaki, Y., Maegawa, K., Sugita, S. & Nerome, K. Advancing usability of an influenza hemagglutinin virus-like particle vaccine expressing a chimeric cytokine. Virol. J. 20, 102. (2023).
Google Scholar
Sun, Y. X. et al. A single vaccination of chimeric bivalent virus-like particle vaccine confers protection against H9N2 and H3N2 avian influenza in commercial broilers and allows a strategy of differentiating infected from vaccinated animals. Front. Immunol. 13, 902515. (2022).
Google Scholar
Ewer, K. et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum. Vaccines Immunother. 13, 3020–3032, (2017).
Google Scholar
Zhu, F. C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621–628, (2017).
Google Scholar
Kumar, D. et al. Immunogenicity of a candidate ebola hemorrhagic fever vaccine in mice based on controlled in vitro expression of ebolavirus glycoprotein. Viral Immunol. 31, 500–512, (2018).
Google Scholar
Mendonça, S. A., Lorincz, R., Boucher, P. & Curiel, D. T. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 6, 97. (2021).
Google Scholar
Dickson, A. et al. The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model. Front. Immunol. 14, 1188392. (2023).
Google Scholar
King, R. G. et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge. Vaccines 9, (2021).
Tukhvatulin, A. I. et al. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerg. Microbes Infect. 11, 2229–2247, (2022).
Google Scholar
Astakhova, E. A. et al. Antibody avidity maturation following booster vaccination with an intranasal adenovirus salnavac vaccine. Vaccines 12, 1362, (2024).
Google Scholar
Yahalom-Ronen, Y. et al. Induction of superior systemic and mucosal protective immunity to SARS-CoV-2 by nasal administration of a VSV-ΔG-spike vaccine. Vaccines 12, 491, (2024).
Google Scholar
Kawai, A. et al. Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses. J. Clin. Investig. 133, (2023).
Hashimoto, S. et al. Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity. Mucosal Immunol. 18, 793–809, (2025).
Google Scholar
Dong, D. et al. Molecular basis of Ad5-nCoV vaccine-induced immunogenicity. Structure (2025).
Google Scholar
Tang, R. et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir. Med. 11, 613–623, (2023).
Google Scholar
Jin, P. F. et al. Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial. Lancet Regional Health West. Pac. 38, 100829. (2023).
Google Scholar
Chen, Z. et al. Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine. Front. Public Health 13, 1478627. (2025).
Google Scholar
Jiang, H. et al. The 6-month antibody durability of heterologous convidecia plus coronavac and homologous coronavac immunizations in people aged 18-59 years and over 60 years based on two randomized controlled trials in China. Vaccines 11, (2023).
Zhang, H. et al. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults. Nat. Commun. 14, 4757 (2023).
Google Scholar
Jin, P. et al. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial. PLoS Med. 19, e1003953, (2022).
Google Scholar
Li, J. X. et al. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. Lancet Infect. Dis. 23, 1143–1152, (2023).
Google Scholar
Zhang, X. et al. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: a case-control study. Hum. Vaccines Immunother. 19, 2194189. (2023).
Google Scholar
Göbel, C. H. et al. Comparison of phenotypes of headaches after COVID-19 vaccinations differentiated according to the vaccine used. Vaccines 13, (2025).
Hassan, A. O., et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169–184, (2020).
Google Scholar
Sunagar, R., Prasad, S. D., Ella, R. & Vadrevu, K. M. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front. Immunol. 13, 1063679. (2022).
Google Scholar
Singh, C. et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®). npj Vaccines 8, 125. (2023).
Google Scholar
Kulkarni, P. S. et al. Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults. Hum. vaccines immunotherapeutics 20, 2304974. (2024).
Google Scholar
van Doremalen, N. et al. ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. Nat. Commun. 13, 4610. (2022).
Google Scholar
van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 13, eabh0755. (2021).
Google Scholar
Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. eBioMedicine 85, 104298. (2022).
Google Scholar
Wang, P. et al. Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines. mBio 10, (2019).
Zhu, F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respiratory Med. 10, 749–760, (2022).
Google Scholar
Chu, K. et al. A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 years. NPJ Vaccines 10, 50. (2025).
Google Scholar
Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Med. 11, 1075–1088, (2023).
Google Scholar
Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372–1387, (2022).
Google Scholar
Carreño, J. M. et al. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Sci. Transl. Med. 15, eabo2847. (2023).
Google Scholar
González-Domínguez, I. et al. Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice. Microbiol. Spectr. 10, e0153822 (2022).
Google Scholar
Duc Dang, A. et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine 40, 3621–3632, (2022).
Google Scholar
González-Domínguez, I. et al. Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models. Front. Immunol. 16, 1524477 (2025).
Google Scholar
2022).
Lin, D. Y. et al. Durability of bivalent boosters against omicron subvariants. N. Engl. J. Med. 388, 1818–1820, (2023).
Google Scholar
Sui, Y. et al. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants. Front. Immunol. 14, 1154496 (2023).
Google Scholar
Zhang, B. D. et al. STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation. Nano Res. 15, 6328–6339, (2022).
Google Scholar
Sun, B. et al. An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA. JCI Insight 9, (2024).
Chen, Y. et al. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. mBio 15, e0240723 (2024).
Google Scholar
Batra, L. et al. Mucosal and Serum Neutralization Immune Responses Elicited by COVID-19 mRNA Vaccination In Vaccinated And Breakthrough-infection Individuals: A Longitudinal Study From Louisville Cohort. Vaccines 13, 559, (2025).
Google Scholar
López-Macías, C. et al. Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine. Sci. Adv. 11, eadq2887. (2025).
Google Scholar
Bricker, T. L. et al. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters. J. Virol. 98, e0120623. (2024).
Google Scholar
Alpuche-Lazcano, S. P. et al. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells. Commun. Med. 3, 116, (2023).
Google Scholar
Collett, S. et al. Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates. Front. Microbiol. 14, 1065609. (2023).
Google Scholar
Huang, Z. et al. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses. Natl Sci. Rev. 11, nwad310. (2024).
Google Scholar
Yang, Y. et al. Enhancing anti-SARS-CoV-2 neutralizing immunity by genetic delivery of enveloped virus-like particles displaying SARS-CoV-2 spikes. Vaccines 11, 1438, (2023).
Google Scholar
Nguyen, H. T., Falzarano, D., Gerdts, V. & Liu, Q. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam. Microbiol. Spectr. 12, e0095924 (2024).
Google Scholar
Karron, R. A. et al. Safety and Immunogenicity of the respiratory syncytial virus vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-seronegative children. J. Infect. Dis. 222, 82–91, (2020).
Google Scholar
Russell, C. D., Unger, S. A., Walton, M. & Schwarze, J. The human immune response to respiratory syncytial virus infection. Clin. Microbiol. Rev. 30, 481–502, (2017).
Google Scholar
Cunningham, C. K. et al. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-seronegative children. J. Infect. Dis. 226, 2069–2078, (2022).
Google Scholar
(2024).
Levy, M. et al. Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters. PLoS Pathog. 20, e1012198, (2024).
Google Scholar
Lee, M. A. et al. Codon pair deoptimization (CPD)-attenuated PRRSV-1 vaccination exhibit immunity to virulent PRRSV challenge in Pigs. Vaccines 11, (2023).
2021).
Hause, A. M. et al. Early safety findings among persons aged ≥60 years who received a respiratory syncytial virus vaccine – United States, May 3, 2023-April 14, 2024. Mmwr. Morbidity Mortal. Wkly. Rep. 73, 489–494, (2024).
Google Scholar
Spearman, P. et al. Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study. Sci. Adv. 9, eadj7611. (2023).
Google Scholar
Xu, Y. et al. Cold-adapted influenza-vectored RSV vaccine protects BALB/c mice and cotton rats from RSV challenge. J. Med. Virol. 96, e29308. (2024).
Google Scholar
Pulkina, A. et al. IgGκ signal peptide enhances the efficacy of an influenza vector vaccine against respiratory syncytial virus infection in mice. Int J. Mol. Sci. 24, 11445, (2023).
Google Scholar
Vasilyev, K. et al. Enhancement of the local CD8(+) T-cellular immune response to mycobacterium tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10.4 and HspX antigens. Vaccines 9, (2021).
Maier, C. et al. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity. Front. Immunol. 13, 920256. (2022).
Google Scholar
Eberlein, V. et al. Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias. Front. Immunol. 15, 1382318. (2024).
Google Scholar
Cheng, X. et al. A first-in-human trial to evaluate the safety and immunogenicity of a G protein-based recombinant respiratory syncytial virus vaccine in healthy adults 18-45 years of age. Vaccines 11, (2023).
Jung, Y. J. et al. Recombinant live attenuated influenza virus expressing conserved G-protein domain in a chimeric hemagglutinin molecule induces G-specific antibodies and confers protection against respiratory syncytial virus. Vaccines 8, (2020).
Chandler, R. et al. Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted RSV prefusion F protein-based candidate vaccine (RSVPreF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial. Clin. Infect. Dis. Off. Pub. Infect. Dis. Soc. Am. (2024).
Athan, E. et al. Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with seasonal inactivated influenza vaccine in older adults. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 78, 1360–1368, (2024).
Google Scholar
Croda, J. Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges. Lancet Infect. Dis. 23, 1099–1100, (2023).
Google Scholar
Srivastava, A., Gowda, D. V., Madhunapantula, S. V., Shinde, C. G. & Iyer, M. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS : Acta Pathologica, Microbiologica, Et. Immunologica Scandinavica 123, 275–288, (2015).
Google Scholar
Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896–915.e819, (2022).
Google Scholar
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279, (2018).
Google Scholar
Tsai, C. J. Y., Loh, J. M. S., Fujihashi, K. & Kiyono, H. Mucosal vaccination: onward and upward. Expert Rev. Vaccines 22, 885–899, (2023).
Google Scholar
García-Silva, I., Govea-Alonso, D. O. & Rosales-Mendoza, S. Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity. Expert Opin. Biol. Ther. 23, 207–222, (2023).
Google Scholar
Azegami, T., Yuki, Y. & Kiyono, H. Challenges in mucosal vaccines for the control of infectious diseases. Int. Immunol. 26, 517–528, (2014).
Google Scholar
Pasetti, M. F. et al. Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally. NPJ Vaccines 10, 23. (2025).
Google Scholar
link
More Stories
Tech Plus Product: A Comprehensive Review of Its Features and Benefits
Here Are the New Features Coming in iOS 26.4
Tested on Palestinians: Epstein, Israel’s Barak pushed spy tech in Nigeria | Features